Do Decreased Breast Microcalcifications After Neoadjuvant Chemotherapy Predict Pathologic Complete Response?

Fushimi, Atsushi; Kudo, Rei; Takeyama, Hiroshi

doi:10.1016/j.clbc.2019.05.015

Cited by 8 publications

(1 citation statement)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the size of the main tumor is reduced by NAC, it is difficult to reduce the final extent of surgery if diffuse microcalcifications remain or the tumors show a scattered shrinkage pattern 14 , 17 , 28 , 29 . Several studies have explored whether microcalcifications are related to tumor responses to NAC for breast cancer 16 , 17 , 30 , 31 . However, they have reported inconsistent conclusions, and the results were not significantly related to those differing based on subtypes or those that were related.…”

Section: Discussionmentioning

confidence: 99%

Oncologic necessity for the complete removal of residual microcalcifications after neoadjuvant chemotherapy for breast cancer

Lee

Park

et al. 2022

Sci Rep

View full text Add to dashboard Cite

The surgical range of breast cancer that shows pathologic complete response (pCR) without change in microcalcifications after neoadjuvant chemotherapy (NAC) is controversial. This study examined whole breast specimens to evaluate the necessity of mastectomy in those cases. The viability of cancer cells around the residual microcalcification was assessed using prospectively collected breast samples to confirm the presence or absence of cancer cells. A total of 144 patients with breast cancer and diffuse microcalcifications were classified into the reduced mass with no change in residual microcalcification (RESMIN, n = 49) and non-RESMIN (n = 95) groups. Five specimens were prospectively evaluated to assess the presence of viable cancer cells around the microcalcification. Tumor responses to NAC were significantly better with high pCR rates in the RESMIN group (p = 0.005 and p = 0.002). The incidence of human epidermal growth factor receptor 2-positive and triple-negative breast cancers was significantly high in the RESMIN group (p = 0.007). Although five (10.2%) patients had locoregional recurrence in the RESMIN group, no local recurrence in the breast was reported. Although pCR was highly estimated, residual cancers, including ductal carcinoma in situ, remained in 80% cases. Therefore, given the weak scientific evidence available currently, complete removal of residual microcalcifications should be considered for oncologic safety.

show abstract

Section: Discussionmentioning

confidence: 99%

Oncologic necessity for the complete removal of residual microcalcifications after neoadjuvant chemotherapy for breast cancer

Lee

Park

et al. 2022

Sci Rep

View full text Add to dashboard Cite

show abstract

The Ultrasonographic Characteristics of Focal Fibrocystic Change of the Breast and Analysis of Misdiagnosis

Lin

et al. 2022

Clinical Breast Cancer

View full text Add to dashboard Cite

Nomogram for Early Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer Combining Both Clinicopathological and Imaging Indicators

Wang

et al. 2022

Current Problems in Cancer

View full text Add to dashboard Cite

Do Decreased Breast Microcalcifications After Neoadjuvant Chemotherapy Predict Pathologic Complete Response?

Cited by 8 publications

References 17 publications

Oncologic necessity for the complete removal of residual microcalcifications after neoadjuvant chemotherapy for breast cancer

Oncologic necessity for the complete removal of residual microcalcifications after neoadjuvant chemotherapy for breast cancer

The Ultrasonographic Characteristics of Focal Fibrocystic Change of the Breast and Analysis of Misdiagnosis

Nomogram for Early Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer Combining Both Clinicopathological and Imaging Indicators

Contact Info

Product

Resources

About